CIK 0001070081 · Large accelerated filer
PTC THERAPEUTICS, INC.
Sign in to watch- Ticker
- PTCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043416587
- Phone
- 9082227000
- Business address
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Former names
- PTC THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,752,145
- in 10 filings, $7.8M under 10b5-1 plans
Net −$7,752,145. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-05 | Reeve Emma Director | Sale 10b5-1 | −734 | $76.00 | $56K | 10,666 |
| 2026-01-05 | Reeve Emma Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −734 | 0 | ||
| 2026-01-05 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +2,266 | $39.42 | $89K | 123,167 |
| 2026-01-05 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,123 | $74.92 | $84K | 122,044 |
| 2026-01-05 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,035 | $76.10 | $79K | 121,009 |
| 2026-01-05 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −108 | $76.79 | $8K | 120,901 |
| 2026-01-05 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,266 | 9,063 | ||
| 2026-01-02 | Gravier Pierre CHIEF FINANCIAL OFFICER | Grant or award | +20,000 | 92,449 | ||
| 2026-01-02 | Gravier Pierre CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2026-01-02 | Young Alethia Director | Grant or award | +4,000 | 21,067 | ||
| 2026-01-02 | Young Alethia Director | Grant or award · Stock Option (Right to Buy) | +3,475 | 3,475 | ||
| 2026-01-02 | Smith Mary L. Director | Grant or award | +4,000 | 21,813 | ||
| 2026-01-02 | Smith Mary L. Director | Grant or award · Stock Option (Right to Buy) | +3,475 | 3,475 | ||
| 2026-01-02 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Grant or award | +63,000 | 405,132 | ||
| 2026-01-02 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +157,500 | 157,500 | ||
| 2026-01-02 | Okey Stephanie Director | Grant or award | +4,000 | 12,000 | ||
| 2026-01-02 | Okey Stephanie Director | Grant or award · Stock Option (Right to Buy) | +3,475 | 3,475 | ||
| 2026-01-02 | Utter Christine Marie SVP, CHIEF ACCOUNTING OFFICER | Grant or award | +13,250 | 76,343 | ||
| 2026-01-02 | Utter Christine Marie SVP, CHIEF ACCOUNTING OFFICER | Grant or award · Stock Option (Right to Buy) | +33,125 | 33,125 | ||
| 2026-01-02 | Golden Lee Scott EVP & CHIEF MEDICAL OFFICER | Grant or award | +18,750 | 95,276 |
Page 12 of 25 · 493 trades